Lineage Cell Therapeutics, Inc.
DE ˙ DB ˙ US53566P1093
1,01 € ↓ -0,04 (-3,63%)
2026-06-03
DEL PRIS
SecurityDE:BT3 / Lineage Cell Therapeutics, Inc.
InstitutionMorgan Stanley
Latest Disclosed Ownership1,868,491 shares
Latest Disclosed Value $ 2,952,215
Morgan Stanley reports 6.51% decrease in ownership of BT3 / Lineage Cell Therapeutics, Inc.

On May 15, 2026 - Morgan Stanley filed a 13F-HR form disclosing ownership of 1,868,491 shares of Lineage Cell Therapeutics, Inc. (DE:BT3) valued at $2,354,299 USD as of March 31, 2026. The entity filed a previous 13F-HR/A on May 27, 2026 disclosing 1,998,663 shares of Lineage Cell Therapeutics, Inc.. This represents a change in shares of -6.51% during the quarter. The current value of the position is $1,887,176 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 1,868,491 -130,172 -6.51 2,952 -11.54 0.0002
2026-05-27 2025-12-31 13F/A-1 LINEAGE CELL THERAPEUTICS IN COM 53566P109 1,998,663 992,212 98.59 3,338 96.29 0.0002
2026-02-13 2025-12-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 1,998,663 992,212 3,338 0.0002
2026-05-27 2025-09-30 13F/A-1 LINEAGE CELL THERAPEUTICS IN COM 53566P109 1,006,451 168,988 20.18 1,701 123.98 0.0001
2025-11-14 2025-09-30 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 1,006,451 168,988 1,701 0.0001
2025-08-15 2025-06-30 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 837,463 -131,318 -13.55 760 73.68 0.0000
2025-05-15 2025-03-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 968,781 308,720 46.77 438 32.02 0.0000
2025-05-15 2024-12-31 13F/A-1 LINEAGE CELL THERAPEUTICS IN COM 53566P109 660,061 -188,230 -22.19 332 -56.84 0.0000
2025-02-14 2024-12-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 660,061 -188,230 332 0.0000
2025-05-14 2024-09-30 13F/A-2 LINEAGE CELL THERAPEUTICS IN COM 53566P109 848,291 321,662 61.08 768 46.10 0.0001
2025-02-14 2024-09-30 13F/A-1 LINEAGE CELL THERAPEUTICS IN COM 53566P109 848,291 321,662 768 0.0001
2024-11-14 2024-09-30 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 848,291 321,662 768 0.0000
2025-05-14 2024-06-30 13F/A-2 LINEAGE CELL THERAPEUTICS IN COM 53566P109 526,629 67,932 14.81 525 -22.57 0.0000
2024-10-17 2024-06-30 13F/A-1 LINEAGE CELL THERAPEUTICS IN COM 53566P109 526,629 67,932 525 0.0000
2024-08-14 2024-06-30 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 526,629 67,932 525 0.0000
2024-10-17 2024-03-31 13F/A-2 LINEAGE CELL THERAPEUTICS IN COM 53566P109 458,697 -18,869 -3.95 679 30.38 0.0001
2024-08-16 2024-03-31 13F/A-1 LINEAGE CELL THERAPEUTICS IN COM 53566P109 458,697 -18,869 679 0.0001
2024-05-15 2024-03-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 458,697 -18,869 679 0.0001
2024-08-16 2023-12-31 13F/A-1 LINEAGE CELL THERAPEUTICS IN COM 53566P109 477,566 199,750 71.90 521 59.02 0.0000
2024-02-13 2023-12-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 477,566 199,750 521 0.0000
2023-11-15 2023-09-30 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 277,816 125,587 82.50 328 52.80 0.0000
2023-08-14 2023-06-30 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 152,229 -153,891 -50.27 215 -53.38 0.0000
2023-05-15 2023-03-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 306,120 174,327 132.27 459 198.05 0.0000
2023-02-14 2022-12-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 131,793 69,231 110.66 154 120.00 0.0000
2022-11-14 2022-09-30 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 62,562 -66,343 -51.47 70 -65.52 0.0000
2022-10-27 2022-06-30 13F/A-1 LINEAGE CELL THERAPEUTICS IN COM 53566P109 128,905 -115,250 -47.20 203 -46.01 0.0000
2022-08-15 2022-06-30 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 128,905 -115,250 203 0.0000
2022-10-27 2022-03-31 13F/A-1 LINEAGE CELL THERAPEUTICS IN COM 53566P109 244,155 -284,402 -53.81 376 -70.97 0.0001
2022-05-13 2022-03-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 244,155 -284,402 376 0.0001
2022-02-14 2021-12-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 528,557 403,214 321.69 1,295 309.81 0.0002
2021-11-15 2021-09-30 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 125,343 -3,419 -2.66 316 -13.90 0.0000
2021-08-23 2021-06-30 13F/A-1 LINEAGE CELL THERAPEUTICS IN COM 53566P109 128,762 18,235 16.50 367 41.70 0.0000
2021-08-16 2021-06-30 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 128,762 18,235 367 0.0000
2021-05-17 2021-03-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 110,527 -19,143 -14.76 259 13.60 0.0000
2021-02-16 2020-12-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 129,670 76,287 142.91 228 356.00 0.0000
2020-11-13 2020-09-30 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 53,383 -31,163 -36.86 50 -31.51 0.0000
2020-08-14 2020-06-30 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 84,546 26,198 44.90 73 52.08 0.0000
2020-05-26 2020-03-31 13F/A-1 LINEAGE CELL THERAPEUTICS IN COM 53566P109 58,348 -138,976 -70.43 48 -72.57 0.0000
2020-05-15 2020-03-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 58,348 -138,976 48 3.6874
2020-02-14 2019-12-31 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 197,324 119,302 152.91 175 130.26 0.0000
2019-11-14 2019-09-30 13F LINEAGE CELL THERAPEUTICS IN COM 53566P109 78,022 31,143 66.43 76 49.02 0.0000
2019-08-14 2019-06-30 13F BIOTIME COM 09066L105 46,879 -18,584 -28.39 51 -40.00 0.0000
2019-05-15 2019-03-31 13F BIOTIME COM 09066L105 65,463 -115,991 -63.92 85 -48.80 0.0000
2019-02-14 2018-12-31 13F BIOTIME COM 09066L105 181,454 -18,156 -9.10 166 -64.61 0.0000
2019-04-23 2018-09-30 13F/A-2 BIOTIME COM 09066L105 199,610 -42,811 -17.66 469 -6.01 0.0001
2018-11-20 2018-09-30 13F/A-1 BIOTIME COM 09066L105 199,610 0 469 0.0001
2018-11-14 2018-09-30 13F BIOTIME COM 09066L105 199,610 -42,811 469
2019-04-23 2018-06-30 13F/A-1 BIOTIME COM 09066L105 242,421 1,741 0.72 499 -22.99 0.0001
2018-08-14 2018-06-30 13F BIOTIME COM 09066L105 242,421 1,741 499
2019-04-23 2018-03-31 13F/A-1 BIOTIME COM 09066L105 240,680 -16,023 -6.24 648 17.39 0.0002
2018-05-14 2018-03-31 13F BIOTIME COM 09066L105 240,680 -16,023 648
2019-04-23 2017-12-31 13F/A-1 BIOTIME COM 09066L105 256,703 94,046 57.82 552 19.74 0.0002
2018-02-14 2017-12-31 13F BIOTIME COM 09066L105 256,703 94,046 552
2017-11-14 2017-09-30 13F BIOTIME COM 09066L105 162,657 62,636 62.62 461 46.35 0.0001
2017-08-11 2017-06-30 13F BIOTIME COM 09066L105 100,021 -47,756 -32.32 315 -38.11 0.0001
2017-05-22 2017-03-31 13F/A-1 BIOTIME COM 09066L105 147,777 -61,014 -29.22 509 -32.49 0.0002
2017-05-12 2017-03-31 13F BIOTIME COM 09066L105 147,777 509
2017-02-22 2016-12-31 13F/A-1 BIOTIME COM 09066L105 208,791 188,383 923.08 754 842.50 0.0002
2017-02-13 2016-12-31 13F BIOTIME COM 09066L105 208,791 754
2016-11-10 2016-09-30 13F BIOTIME COM 09066L105 20,408 9,870 93.66 80 185.71 0.0000
2016-08-12 2016-06-30 13F BIOTIME COM 09066L105 10,538 6,378 153.32 28 133.33 0.0000
2016-05-12 2016-03-31 13F BIOTIME COM 09066L105 4,160 -18,394 -81.56 12 -86.96 0.0000
2016-02-09 2015-12-31 13F BIOTIME COM 09066L105 22,554 8,147 56.55 92 113.95 0.0000
2016-02-08 2015-09-30 13F/A-1 BIOTIME COM 09066L105 14,407 -71,672 -83.26 43 -86.26 0.0000
2015-11-09 2015-09-30 13F BIOTIME COM 09066L105 14,407 43
2015-08-12 2015-06-30 13F BIOTIME COM 09066L105 86,079 48,886 131.44 313 69.19 0.0001
2015-05-14 2015-03-31 13F BIOTIME COM 09066L105 37,193 -65,919 -63.93 185 -51.82 0.0001
2015-02-13 2014-12-31 13F BIOTIME COM 09066L105 103,112 -78,218 -43.14 384 -32.63 0.0001
2014-12-16 2014-09-30 13F/A-1 BIOTIME COM 09066L105 181,330 -71,173 -28.19 570 -25.97 0.0002
2014-11-14 2014-09-30 13F BIOTIME COM 09066L105 181,330 570
2014-08-12 2014-06-30 13F BIOTIME COM 09066L105 252,503 -4,412 -1.72 770 -8.88 0.0013
2014-05-13 2014-03-31 13F BIOTIME COM 09066L105 256,915 158,276 160.46 845 138.03 0.0004
2014-02-13 2013-12-31 13F BIOTIME COM 09066L105 98,639 68,011 222.05 355 206.03 0.0002
2013-11-13 2013-09-30 13F BIOTIME INC COM ST COM 09066L105 30,628 16,357 114.62 116 103.51 0.0001
2013-08-08 2013-06-30 13F BIOTIME INC COM ST COM 09066L105 14,271 14,271 57 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.